Development of non-phosphorylated cyclic thioether peptide binding to the Grb2-SH2 domain |
| |
Authors: | Feng-Di T. Lung C. Richter King Peter P. Roller |
| |
Affiliation: | (1) Laboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, MD, 20892, U.S.A;(2) Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, 20007, U.S.A |
| |
Abstract: | One of the critical intracellular signaling pathways involves specific interactions between growth factor receptors and the adaptor protein Grb2. These interactions normally involve specific tyrosine phosphorylated regions in receptors and other cognate proteins. Following the lead of our recent findings that a phage library based non-phosphorylated disulfide linked 11-mer peptide inhibited such interactions, we report here the synthesis of novel redox-stable cyclic peptide analogs. These include thioether cyclized and backbone cyclized structures. The thioether analog was prepared under mild conditions from an N-terminally chloroacetylated and C-terminally cysteine extended peptide precursor. The thioether peptide showed equipotent binding affinity for the Grb2-SH2 domain (IC50 = 10–15 M) when compared to the disulfide cyclized lead-peptide. The bioactive thioether linked peptide was demonstrated to offer advantages to the disulfide cyclized peptides under physiological conditions. |
| |
Keywords: | cyclic peptides inhibitors N-chloroacetyl peptide solid-phase peptide synthesis |
本文献已被 SpringerLink 等数据库收录! |
|